More is not always better—what can be learned from the D-CARE trial

Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Correspondence to: Georg Pfeiler. Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Email: georg.pfeiler@meduniwien.ac.at. Provenance and peer review: This article was commissioned and reviewed by the editorial office, Annals of Translational Medicine. The article did not undergo external peer review. Comment on: Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:60-72.